Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiocarcinoma | 2 | 2020 | 20 | 0.900 |
Why?
|
| Bile Duct Neoplasms | 2 | 2020 | 39 | 0.890 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 3 | 0.760 |
Why?
|
| Adrenergic Antagonists | 1 | 2020 | 4 | 0.760 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2020 | 3 | 0.740 |
Why?
|
| CA-19-9 Antigen | 1 | 2020 | 5 | 0.740 |
Why?
|
| Heart Neoplasms | 1 | 2020 | 33 | 0.740 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2020 | 35 | 0.730 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 17 | 0.730 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 799 | 0.720 |
Why?
|
| Salvage Therapy | 1 | 2020 | 82 | 0.700 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2018 | 4 | 0.670 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2018 | 5 | 0.670 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.670 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2018 | 1 | 0.640 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2018 | 1 | 0.640 |
Why?
|
| Mastocytosis, Systemic | 1 | 2018 | 3 | 0.640 |
Why?
|
| History, Ancient | 1 | 2018 | 25 | 0.640 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1070 | 0.640 |
Why?
|
| Hypophosphatemia | 1 | 2017 | 6 | 0.630 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 163 | 0.620 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 51 | 0.610 |
Why?
|
| Hospitals | 1 | 2019 | 265 | 0.600 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2017 | 34 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 467 | 0.570 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 334 | 0.560 |
Why?
|
| Melanoma | 1 | 2019 | 335 | 0.550 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 450 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 332 | 0.540 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 375 | 0.520 |
Why?
|
| Prognosis | 8 | 2020 | 2093 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 624 | 0.480 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 4843 | 0.380 |
Why?
|
| Aged | 12 | 2020 | 14842 | 0.370 |
Why?
|
| Survival Rate | 4 | 2020 | 1055 | 0.350 |
Why?
|
| Survival Analysis | 4 | 2018 | 714 | 0.350 |
Why?
|
| Young Adult | 9 | 2019 | 5708 | 0.340 |
Why?
|
| Middle Aged | 13 | 2020 | 21119 | 0.330 |
Why?
|
| Histiocytic Sarcoma | 2 | 2018 | 3 | 0.330 |
Why?
|
| SEER Program | 5 | 2019 | 150 | 0.310 |
Why?
|
| Humans | 20 | 2020 | 68525 | 0.310 |
Why?
|
| Adolescent | 9 | 2019 | 8903 | 0.300 |
Why?
|
| United States | 11 | 2019 | 7335 | 0.290 |
Why?
|
| Female | 14 | 2020 | 38015 | 0.280 |
Why?
|
| Incidence | 6 | 2019 | 1582 | 0.270 |
Why?
|
| Adult | 11 | 2019 | 21375 | 0.260 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 110 | 0.250 |
Why?
|
| Male | 12 | 2020 | 37281 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 61 | 0.200 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 131 | 0.200 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2020 | 9 | 0.190 |
Why?
|
| Margins of Excision | 1 | 2020 | 15 | 0.180 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 62 | 0.180 |
Why?
|
| Radiotherapy | 1 | 2020 | 86 | 0.180 |
Why?
|
| Langerhans Cell Sarcoma | 1 | 2019 | 1 | 0.180 |
Why?
|
| Hospital Bed Capacity | 1 | 2019 | 15 | 0.170 |
Why?
|
| Filgrastim | 1 | 2019 | 22 | 0.170 |
Why?
|
| Propensity Score | 1 | 2019 | 116 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 129 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 125 | 0.170 |
Why?
|
| Neutropenia | 1 | 2019 | 72 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2018 | 621 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 25 | 0.170 |
Why?
|
| Drug Industry | 1 | 2019 | 54 | 0.170 |
Why?
|
| Long Term Adverse Effects | 1 | 2018 | 6 | 0.170 |
Why?
|
| Histiocytes | 1 | 2018 | 8 | 0.170 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 1 | 0.170 |
Why?
|
| Leukemia, T-Cell | 1 | 2018 | 21 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2018 | 19 | 0.160 |
Why?
|
| Drug Costs | 1 | 2019 | 87 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2020 | 258 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 110 | 0.160 |
Why?
|
| Behavioral Symptoms | 1 | 2018 | 32 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2020 | 212 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 49 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 47 | 0.160 |
Why?
|
| Suicide | 1 | 2018 | 115 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7028 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 785 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1465 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 300 | 0.140 |
Why?
|
| Registries | 1 | 2019 | 730 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.130 |
Why?
|
| Child | 4 | 2018 | 6400 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 446 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 595 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2018 | 3185 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 503 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 951 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2019 | 7264 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2453 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 2891 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1172 | 0.090 |
Why?
|
| Risk Factors | 1 | 2020 | 5719 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1533 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 306 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 536 | 0.080 |
Why?
|
| Disease Management | 2 | 2019 | 248 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2019 | 285 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 791 | 0.070 |
Why?
|
| Hematologic Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 18 | 0.040 |
Why?
|
| Japan | 1 | 2019 | 68 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 12 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 18 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 195 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 266 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 41 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 23 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 272 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 106 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 955 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 445 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1609 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 2004 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 1026 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Neoplasms | 1 | 2019 | 1660 | 0.020 |
Why?
|